A daily oral GLP-1 pill can help people with obesity lose about 12% of their body weight, according to early data shared by drugmaker Eli Lilly today.

The medication, called orforglipron, may be a more appealing alternative to injectable GLP-1 drugs. It could also be manufactured and distributed more easily.

Orforglipron “could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments,” Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, said in a statement.

However, Lilly's topline results today indicate that orforglipron delivers a fraction of the weight loss offered by drugs like Wegovy and Zepbound, which can cause 14%-20% weight loss.

The orforglipron outcome looks “pretty

See Full Page